MCID: RBL001
MIFTS: 61

Rubella

Categories: Rare diseases, Infectious diseases, Fetal diseases, Neuronal diseases

Aliases & Classifications for Rubella

Summaries for Rubella

MedlinePlus : 40 Rubella is an infection caused by a virus. It is usually mild with fever and a rash. About half of the people who get rubella do not have symptoms. If you do get them, symptoms may include A rash that starts on the face and spreads to the body Mild fever Aching joints, especially in young women Swollen glands Rubella is most dangerous for a pregnant woman's baby. It can cause miscarriage or birth defects. Rubella spreads when an infected person coughs or sneezes. People without symptoms can still spread it. There is no treatment, but the measles-mumps-rubella (MMR) vaccine can prevent it. Centers for Disease Control and Prevention

MalaCards based summary : Rubella, also known as german measles, is related to measles and acute disseminated encephalomyelitis, and has symptoms including rash on the face which spreads to the trunk, fever and lymphadenopathy. An important gene associated with Rubella is CD40LG (CD40 Ligand), and among its related pathways/superpathways are Innate Immune System and PI3K-Akt signaling pathway. The drugs Vaccines and Immunoglobulins have been mentioned in the context of this disorder. Affiliated tissues include skin, skin and eye.

Disease Ontology : 12 A viral infectious disease that results_in infection located in skin, has material basis in Rubella virus, which is transmitted_by droplet spread of oronasal secretions from the infected person through coughing and sneezing, and transmitted_by congenital method. The infection has symptom rash on the face which spreads to the trunk and limbs, has symptom fever, has symptom lymphadenopathy, has symptom joint pains, has symptom headache, and has symptom conjunctivitis.

CDC : 3 Rubella is a contagious disease caused by a virus. Most people who get rubella usually have a mild illness, with symptoms that can include a low-grade fever, sore throat, and a rash that starts on the face and spreads to the rest of the body. Rubella can cause a miscarriage or serious birth defects in a developing baby if a woman is infected while she is pregnant. The best protection against rubella is MMR (measles-mumps-rubella) vaccine.

Wikipedia : 72 Rubella, also known as German measles or three-day measles, is an infection caused by the rubella virus.... more...

Related Diseases for Rubella

Diseases in the Rubella family:

Congenital Rubella

Diseases related to Rubella via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 335)
# Related Disease Score Top Affiliating Genes
1 measles 32.5 CD40LG IFNAR2 IL4
2 acute disseminated encephalomyelitis 32.4 HLA-DRB1 IL10 MOG
3 mumps 32.1 CD40LG HLA-DRB1 IFNAR2 IL10RB
4 meningitis 30.3 CD40LG IL10 TNF
5 myelitis 30.2 HLA-DPB1 MOG TNF
6 iridocyclitis 30.2 CD40LG HLA-B HLA-DPB1
7 tetanus 30.1 CD40LG IL10 IL4
8 optic neuritis 30.0 HLA-DRB1 MOG TNF
9 anterior uveitis 29.9 HLA-A HLA-B TNF
10 chlamydia 29.9 CD40LG IL10 TNF
11 poliomyelitis 29.8 IL10 IL4 TNF
12 neuritis 29.8 IL4 MOG TNF
13 toxoplasmosis 29.7 CD40LG IL10 IL4 TNF
14 choroiditis 29.7 IL10 TNF
15 uveitis 29.6 HLA-B IL10 IL4 TNF
16 pneumonia 29.6 CD40LG IL10 TNF
17 myocarditis 29.6 CD40LG HLA-B TNF
18 intermediate uveitis 29.5 HLA-B IL10 TNF
19 multiple sclerosis 29.2 HLA-DRB1 IL10 IL4 MOG TNF
20 mycobacterium tuberculosis 1 29.1 IL10 IL4 TNF
21 panuveitis 29.1 CD40LG HLA-B HLA-DRB1 IL10 TNF
22 rheumatic disease 28.9 CD40LG HLA-B HLA-DRB1 IL10 TNF
23 asthma 28.6 CD40LG HLA-DPB1 HLA-DRB1 IL10 IL4 TNF
24 autoimmune disease 28.3 CD40LG HLA-B HLA-DRB1 IL10 IL4 MOG
25 human immunodeficiency virus type 1 28.1 HLA-A HLA-B IL10 TNF TRIM5
26 congenital rubella 12.6
27 rubella panencephalitis 12.0
28 primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection 11.9
29 congenital toxoplasmosis 11.1
30 cytomegalic inclusion disease 11.1
31 microcephaly 11.0
32 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 10.8
33 immunodeficiency 45 10.8
34 congenital intrauterine infection-like syndrome 10.8
35 togaviridae disease 10.8
36 immune-mediated encephalomyelitis 10.8
37 postinfectious encephalomyelitis 10.8
38 ross river fever 10.4 CD40LG IL10
39 berylliosis 10.4 HLA-DPB1 HLA-DRB1
40 trench fever 10.4 CD40LG TNF
41 encephalitozoonosis 10.4 CD40LG TNF
42 iritis 10.4 CD40LG HLA-B
43 idiopathic inflammatory myopathy 10.4 HLA-B HLA-DRB1
44 rheumatoid lung disease 10.4 CD40LG TNF
45 juvenile myasthenia gravis 10.4 HLA-DRB1 IL10
46 aging 10.4
47 miller fisher syndrome 10.4 CD40LG TNF
48 phenytoin or carbamazepine toxicity 10.4 HLA-A HLA-B
49 punctate inner choroidopathy 10.4 IL10 TNF
50 sporotrichosis 10.3 CD40LG IL10

Graphical network of the top 20 diseases related to Rubella:



Diseases related to Rubella

Symptoms & Phenotypes for Rubella

Symptoms:

12
  • rash on the face which spreads to the trunk
  • fever
  • lymphadenopathy
  • joint pains
  • headache
  • conjunctivitis

UMLS symptoms related to Rubella:


pruritus, fever, exanthema

Drugs & Therapeutics for Rubella

Drugs for Rubella (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 69)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
2 Immunoglobulins Phase 4,Phase 2,Phase 1
3 Antibodies Phase 4,Phase 2,Phase 1
4 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2
5 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
6 Liver Extracts Phase 4
7
Tetracycline Approved, Vet_approved Phase 3,Phase 2 60-54-8 5353990
8
Aluminum hydroxide Approved, Investigational Phase 3,Phase 2 21645-51-2
9
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 68-26-8, 11103-57-4 445354
10
Lactitol Investigational Phase 3,Phase 2 585-86-4 3871
11 PENTA Phase 3,Phase 2
12 Anti-Bacterial Agents Phase 3,Phase 2
13 Anti-Infective Agents Phase 3,Phase 2
14 Protective Agents Phase 3,Phase 2
15 Retinol palmitate Phase 3
16 Micronutrients Phase 3
17 Trace Elements Phase 3
18 Vitamins Phase 3
19 Antioxidants Phase 3
20 retinol Nutraceutical Phase 3
21
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
22
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
23
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
24
Bevacizumab Approved, Investigational Phase 2 216974-75-3
25
Altretamine Approved Phase 2 645-05-6 2123
26
Mycophenolic acid Approved Phase 2 24280-93-1 446541
27
Mycophenolate mofetil Approved, Investigational Phase 2 128794-94-5 5281078
28
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
29
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
30
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
31
Obinutuzumab Approved, Investigational Phase 2,Phase 1 949142-50-1
32 Alkylating Agents Phase 2
33 Fibrinolytic Agents Phase 2
34 Angiogenesis Inhibitors Phase 2
35 Angiogenesis Modulating Agents Phase 2
36 Anticoagulants Phase 2
37 Prednisolone acetate Phase 2
38 glucocorticoids Phase 2
39 Methylprednisolone acetate Phase 2
40 Methylprednisolone Hemisuccinate Phase 2
41 Gastrointestinal Agents Phase 2
42 Neuroprotective Agents Phase 2
43 Hormone Antagonists Phase 2
44 Hormones Phase 2
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
46 Peripheral Nervous System Agents Phase 2
47 Antiemetics Phase 2
48 Prednisolone hemisuccinate Phase 2
49 Prednisolone phosphate Phase 2
50 Anti-Inflammatory Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 142)

# Name Status NCT ID Phase Drugs
1 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
2 Coadministration of Measles-rubella and Rotavirus Vaccines Completed NCT01700621 Phase 4
3 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine Completed NCT02880865 Phase 4
4 Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis Completed NCT00731965 Phase 4
5 Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00126997 Phase 4
6 Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine Completed NCT03160820 Phase 4
7 Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Completed NCT01777529 Phase 4
8 Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines Completed NCT02643433 Phase 4
9 Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Completed NCT00313950 Phase 4
10 Measles, Mumps, and Rubella (MMR) Immunity in College Students Completed NCT00962819 Phase 4
11 MMR Vaccination Among HIV-infected Adults Completed NCT02724852 Phase 4
12 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Completed NCT00326183 Phase 4
13 Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Completed NCT00388440 Phase 4
14 Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067) Completed NCT00312858 Phase 4
15 IPV Clinical Trial - The Gambia Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
16 MMR and Varicella Vaccine in Premature Infants Completed NCT00156559 Phase 4
17 Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children Completed NCT02253407 Phase 4
18 Safety Study of a Refrigerator-stable Formulation of VARIVAX® Completed NCT00432731 Phase 4
19 Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV Completed NCT00329251 Phase 4
20 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Recruiting NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
21 Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines Recruiting NCT03368495 Phase 4
22 Homeopathic Vaccine Trial Recruiting NCT02825368 Phase 4
23 Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients Recruiting NCT01770119 Phase 4
24 Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR Active, not recruiting NCT02325310 Phase 4
25 The Phase IVd of Inactivated Enterovirus 71 Vaccine Enrolling by invitation NCT03296410 Phase 4
26 Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age Not yet recruiting NCT03071575 Phase 4
27 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination Not yet recruiting NCT03350698 Phase 4
28 Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines Terminated NCT00138255 Phase 4
29 Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants Unknown status NCT01763268 Phase 2, Phase 3
30 Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older Completed NCT02058563 Phase 3
31 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127010 Phase 3
32 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127023 Phase 3
33 Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Completed NCT01188343 Phase 3
34 Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) Completed NCT01536405 Phase 3
35 Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. Completed NCT01991899 Phase 3
36 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Completed NCT01681992 Phase 3
37 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age Completed NCT02184572 Phase 3
38 Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) Completed NCT00092430 Phase 3
39 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age Completed NCT01621802 Phase 3
40 Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Completed NCT00751348 Phase 3
41 Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children Completed NCT00192491 Phase 3
42 Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children Completed NCT00197015 Phase 3
43 Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox Completed NCT00226499 Phase 3
44 Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children Completed NCT01506193 Phase 3
45 ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED) Completed NCT00975507 Phase 3
46 Safety Study of ProQuad® rHA in Infants (V221-037) Completed NCT00560755 Phase 3
47 Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Completed NCT00969436 Phase 3
48 Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Children 12 to 15 Months of Age Completed NCT01702428 Phase 3
49 ProQuad® Intramuscular vs Subcutaneous Completed NCT00402831 Phase 3
50 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly Completed NCT00432042 Phase 3

Search NIH Clinical Center for Rubella

Cochrane evidence based reviews: rubella

Genetic Tests for Rubella

Anatomical Context for Rubella

The Foundational Model of Anatomy Ontology organs/tissues related to Rubella:

18
Skin

MalaCards organs/tissues related to Rubella:

38
Skin, Eye, Brain, Lymph Node, Heart, Testes, Liver

Publications for Rubella

Articles related to Rubella:

(show top 50) (show all 1302)
# Title Authors Year
1
Rubella natural immunity among adolescent girls in Tanzania: the need to vaccinate child bearing aged women. ( 29298693 )
2018
2
Myelin Oligodendrocyte Glycoprotein-Independent Rubella Infection of Keratinocytes and Resistance of First-Trimester Trophoblast Cells to Rubella Virus In Vitro. ( 29300335 )
2018
3
Assessment of Humoral Immunity to Hepatitis B, Measles, Rubella, and Mumps in Children After Chemotherapy. ( 29309372 )
2018
4
The role of extended and whole genome sequencing for tracking transmission of measles and rubella viruses: report from the Global Measles and Rubella Laboratory Network meeting, 2017. ( 29424220 )
2018
5
Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine. ( 29317117 )
2018
6
Measles and Rubella Global Strategic Plan 2012-2020 midterm review report: Background and summary. ( 29307368 )
2018
7
Measles and Rubella Global Strategic Plan 2012-2020 midterm review. ( 29307367 )
2018
8
An Intraocular Inflammatory Profile of Rubella Associated Uveitis. ( 29370571 )
2018
9
Seroprevalence of antibodies to measles and rubella eight months after a vaccination campaign in the southeast of Iran. ( 29420120 )
2018
10
Polymorphisms in the Wilms Tumor Gene Are Associated With Interindividual Variations in Rubella Virus-Specific Cellular Immunity After Measles-Mumps-Rubella II Vaccination. ( 29253144 )
2018
11
Intravitreal aflibercept for the treatment of choroidal neovascularization associated with rubella retinopathy. ( 29411259 )
2018
12
Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial. ( 29395526 )
2018
13
Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. ( 29426830 )
2018
14
An infant with congenital rubella syndrome in developing India. ( 29184005 )
2017
15
Molecular Epidemiology of Rubella Virus Strains Detected Around the Time of the 2012-2013 Epidemic in Japan. ( 28848523 )
2017
16
Clinical profile of congenital rubella syndrome in Yogyakarta, Indonesia. ( 29068106 )
2017
17
Underreporting of congenital rubella in Italy, 2010-2014. ( 28551878 )
2017
18
The utility of measles and rubella IgM serology in an elimination setting, Ontario, Canada, 2009-2014. ( 28850604 )
2017
19
Susceptibility of Rubella Among Pregnant Women Attending the Antenatal Clinic in a Tertiary Care Hospital, Jabalpur, Central India. ( 27925863 )
2017
20
Comparison of cidofovir and the measles, mumps, and rubella vaccine in the treatment of recurrent respiratory papillomatosis. ( 28231366 )
2017
21
Prevalence of Rubella Antibodies Among Children in the Democratic Republic of the Congo. ( 28746265 )
2017
22
Pain caused by measles, mumps, and rubella vaccines: A systematic literature review. ( 28893478 )
2017
23
FUNDUS AUTOFLUORESCENCE IN RUBELLA RETINOPATHY: Correlation With Photoreceptor Structure and Function. ( 28005720 )
2017
24
Impact of the two-dose rubella vaccination regimen on incidence of rubella seronegativity in gravidae aged 25 years and younger. ( 28854204 )
2017
25
Micro-planning in a wide age range measles rubella (MR) campaign using mobile phone app, a case of Kenya, 2016. ( 29296151 )
2017
26
Transitioning Lessons Learned and Assets of the Global Polio Eradication Initiative to Global and Regional Measles and Rubella Elimination. ( 28838195 )
2017
27
Two Imported Cases of Congenital Rubella Syndrome and Infection-Control Challenges in New York State, 2013-2015. ( 28510706 )
2017
28
Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands. ( 28855159 )
2017
29
Mumps Virus Nucleoprotein and Hemagglutinin-Specific Antibody Response Following a Third Dose of Measles Mumps Rubella Vaccine. ( 29308410 )
2017
30
Sociodemographic and economic characteristics of susceptibility to rubella among women preparing for pregnancy in rural China. ( 28739423 )
2017
31
Pivoting from polio eradication to measles and rubella elimination: a transition that makes sense both for children and immunization program improvement. ( 29296145 )
2017
32
Progress towards rubella elimination after implementation of rubella immunization for over 20 years in Shandong province, China. ( 29269776 )
2017
33
Seroprevalence of Rubella and Cytomegalia in Young Women from BiaA8a Podlaska District. ( 29319529 )
2017
34
Progress in rubella and congenital rubella syndrome control and elimination a89 worldwide, 2000a892016. ( 29148274 )
2017
35
Analysis of VSV pseudotype virus infection mediated by rubella virus envelope proteins. ( 28912595 )
2017
36
Lacrimal drainage anomalies in congenital rubella syndrome. ( 29184387 )
2017
37
Progress in Rubella and Congenital Rubella Syndrome Control and Elimination - Worldwide, 2000-2016. ( 29145358 )
2017
38
Mumps, Measles, and Rubella Vaccine for the Treatment of a Recalcitrant Subungual Wart. ( 28709617 )
2017
39
Expansion of Surveillance for Vaccine-preventable Diseases: Building on the Global Polio Laboratory Network and the Global Measles and Rubella Laboratory Network Platforms. ( 28838191 )
2017
40
50 Years Ago in The Journal of Pediatrics: Cerebral Lesions in Congenital Rubella Syndrome. ( 28129869 )
2017
41
The end of measles and congenital rubella: an achievable dream? ( 28067934 )
2017
42
Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia. ( 28806450 )
2017
43
Utilization and impact of European immunization week to increase measles, mumps, rubella vaccine uptake in Austria in 2016. ( 28797728 )
2017
44
Impact of an Intervention to Use a Measles, Rubella, and Polio Mass Vaccination Campaign to Strengthen Routine Immunization Services in Nepal. ( 28838201 )
2017
45
Congenital rubella syndrome: an unusual cause of neonatal fulminant hepatic failure. ( 28678001 )
2017
46
Rubella, herpes simplex virus type 2 and preeclampsia. ( 28747200 )
2017
47
Voluntary termination of pregnancy: An opportunity for Measles, Mumps and Rubella vaccination in an Italian healthcare local unit. ( 29261361 )
2017
48
The burden of congenital rubella syndrome in the Philippines: results from a retrospective assessment. ( 29184700 )
2017
49
Complete Genome Sequence of a Genotype 2B Rubella Virus Isolated in South Korea in 2015. ( 28935733 )
2017
50
Measles, Rubella and Varicella IgG Seroprevalence in a Large Refugee Cohort in Germany in 2015: A Cross-Sectional Study. ( 28875465 )
2017

Variations for Rubella

Expression for Rubella

Search GEO for disease gene expression data for Rubella.

Pathways for Rubella

Pathways related to Rubella according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.88 CALR CD40LG HLA-A HLA-B HLA-DPB1 HLA-DRB1
2
Show member pathways
12.88 HLA-A HLA-B IFNAR2 IL4 TNF
3
Show member pathways
12.66 C1QBP HLA-A HLA-B HLA-DPB1 HLA-DRB1 IFNAR2
4
Show member pathways
12.56 HLA-DPB1 HLA-DRB1 IL10 IL10RB IL4 TNF
5 12.51 C1QBP CD40LG IL10 IL4 TNF
6
Show member pathways
12.51 CD40LG HLA-A HLA-B HLA-DPB1 HLA-DRB1 IFNAR2
7
Show member pathways
12.49 HLA-A HLA-B IFNAR2 TNF
8
Show member pathways
12.47 HLA-A HLA-B IFNAR2 IL4 TNF
9
Show member pathways
12.45 CALR IFNAR2 IL10 TNF
10
Show member pathways
12.44 HLA-A HLA-B HLA-DPB1 HLA-DRB1 IFNAR2 TRIM22
11
Show member pathways
12.42 CD40LG HLA-DPB1 HLA-DRB1 IFNAR2 IL10 IL10RB
12 12.38 CALR HLA-A HLA-B HLA-DPB1 HLA-DRB1 TNF
13
Show member pathways
12.36 CD40LG IL10 IL4 TNF
14
Show member pathways
12.35 CALR CD40LG HLA-A HLA-B HLA-DPB1 HLA-DRB1
15
Show member pathways
12.3 IFNAR2 IL10 IL10RB IL4
16 12.22 HLA-A HLA-B HLA-DPB1 HLA-DRB1 IL10 IL10RB
17 12.21 HLA-DPB1 HLA-DRB1 IL10 IL10RB TNF
18 12.12 CALR HLA-A HLA-B HLA-DPB1 HLA-DRB1
19 12.07 CD40LG HLA-A HLA-B HLA-DPB1 HLA-DRB1
20
Show member pathways
12.01 HLA-A HLA-B IFNAR2 IL10 IL4 TNF
21 11.99 CD40LG HLA-A HLA-B
22
Show member pathways
11.97 CD40LG HLA-DPB1 HLA-DRB1 IL10 IL10RB IL4
23 11.92 IL10 IL4 TNF
24 11.91 IL10 IL4 TNF
25
Show member pathways
11.9 HLA-A HLA-DRB1 IL4
26 11.86 HLA-DPB1 HLA-DRB1 IL4 TNF
27 11.79 HLA-DPB1 HLA-DRB1 TNF
28 11.73 IL10 IL4 TNF
29
Show member pathways
11.7 CD40LG IL4 TNF
30 11.69 CD40LG IL10 IL4 TNF
31 11.61 CD40LG IL10 IL4
32
Show member pathways
11.59 HLA-A IFNAR2 TNF
33 11.55 HLA-DPB1 HLA-DRB1 IL10
34 11.52 IL10 IL10RB IL4 TNF
35 11.48 CD40LG IL10 TNF
36 11.33 IL10 IL10RB TNF
37 11.23 HLA-DRB1 IL10 IL4 TNF
38 11.16 CALR HLA-A HLA-B
39 11.15 CD40LG IL10 IL4 TNF

GO Terms for Rubella

Cellular components related to Rubella according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi apparatus GO:0005794 9.91 CALR HLA-A HLA-B HLA-DPB1 HLA-DRB1 TRIM22
2 external side of plasma membrane GO:0009897 9.62 CALR CD40LG HLA-DRB1 TNF
3 cell surface GO:0009986 9.56 C1QBP CALR CD40LG HLA-A HLA-B HLA-DPB1
4 ER to Golgi transport vesicle membrane GO:0012507 9.46 HLA-A HLA-B HLA-DPB1 HLA-DRB1
5 phagocytic vesicle membrane GO:0030670 9.43 CALR HLA-A HLA-B
6 MHC class II protein complex GO:0042613 9.4 HLA-DPB1 HLA-DRB1
7 MHC class I protein complex GO:0042612 9.37 HLA-A HLA-B
8 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.02 CALR HLA-A HLA-B HLA-DPB1 HLA-DRB1

Biological processes related to Rubella according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 regulation of immune response GO:0050776 9.85 CD40LG HLA-A HLA-B IL4
2 response to virus GO:0009615 9.83 IFNAR2 TNF TRIM22
3 response to organic substance GO:0010033 9.81 CALR IL10 TNF
4 defense response to virus GO:0051607 9.81 IFNAR2 IL10RB TRIM22 TRIM5
5 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.8 CALR HLA-A HLA-B
6 immune system process GO:0002376 9.8 C1QBP HLA-A HLA-B HLA-DPB1 HLA-DRB1 TRIM5
7 T cell costimulation GO:0031295 9.79 CD40LG HLA-DPB1 HLA-DRB1
8 B cell differentiation GO:0030183 9.78 CD40LG IL10 IL4
9 type I interferon signaling pathway GO:0060337 9.77 HLA-A HLA-B IFNAR2
10 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.76 CD40LG TNF TRIM22 TRIM5
11 positive regulation of T cell proliferation GO:0042102 9.75 CD40LG HLA-DPB1 IL4
12 viral process GO:0016032 9.7 C1QBP HLA-A HLA-B HLA-DRB1 MOG TRIM22
13 positive regulation of DNA binding transcription factor activity GO:0051091 9.67 IL10 TNF TRIM22 TRIM5
14 negative regulation of growth of symbiont in host GO:0044130 9.65 IL10 TNF
15 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.65 HLA-DPB1 HLA-DRB1
16 negative regulation of interleukin-12 production GO:0032695 9.64 C1QBP IL10
17 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.64 IL10 TNF
18 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.63 HLA-A HLA-B
19 endothelial cell apoptotic process GO:0072577 9.61 IL10 TNF
20 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.61 CALR HLA-A HLA-B
21 positive regulation of dendritic cell chemotaxis GO:2000510 9.59 C1QBP CALR
22 positive regulation of MHC class II biosynthetic process GO:0045348 9.58 IL10 IL4
23 negative regulation of interferon-gamma production GO:0032689 9.58 C1QBP HLA-DRB1 IL10
24 negative regulation of cytokine secretion involved in immune response GO:0002740 9.57 IL10 TNF
25 type 2 immune response GO:0042092 9.56 IL10 IL4
26 antigen processing and presentation GO:0019882 9.56 HLA-A HLA-B HLA-DPB1 HLA-DRB1
27 protection from natural killer cell mediated cytotoxicity GO:0042270 9.54 HLA-A HLA-B
28 regulation of immunoglobulin secretion GO:0051023 9.52 CD40LG TNF
29 regulation of isotype switching GO:0045191 9.49 IL10 IL4
30 receptor biosynthetic process GO:0032800 9.48 IL10 TNF
31 interferon-gamma-mediated signaling pathway GO:0060333 9.43 HLA-A HLA-B HLA-DPB1 HLA-DRB1 TRIM22 TRIM5
32 immune response GO:0006955 9.36 C1QBP CD40LG HLA-A HLA-B HLA-DPB1 HLA-DRB1

Molecular functions related to Rubella according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 CD40LG IL10 IL4 TNF
2 complement component C1q binding GO:0001849 9.16 C1QBP CALR
3 peptide antigen binding GO:0042605 8.92 HLA-A HLA-B HLA-DPB1 HLA-DRB1

Sources for Rubella

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....